0001193125-22-211731.txt : 20220804 0001193125-22-211731.hdr.sgml : 20220804 20220804060420 ACCESSION NUMBER: 0001193125-22-211731 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PIMCO Flexible Emerging Markets Income Fund CENTRAL INDEX KEY: 0001851077 IRS NUMBER: 000000000 STATE OF INCORPORATION: MA FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-254586 FILM NUMBER: 221134452 BUSINESS ADDRESS: STREET 1: 1633 BROADWAY CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 844-312-2113 MAIL ADDRESS: STREET 1: 1633 BROADWAY CITY: NEW YORK STATE: NY ZIP: 10019 424B3 1 d363690d424b3.htm 424B3 424B3

Filed pursuant to Rule 424(b)(3)
File No. 333-254586

PIMCO Flexible Emerging Markets Income Fund (the “Fund”)

Supplement dated August 4, 2022 to the

Prospectus and Statement of Additional Information (the “SAI”),

each dated July 29, 2021 (as supplemented through March 11, 2022)

Previously, PIMCO contractually agreed to waive: (1) 70% of the management fees it was entitled to receive from the Fund for the one-year period following the date as of which the Fund’s registration statement on Form N-2 was initially declared effective; and (2) 35% of the management fees it was entitled to receive from the Fund for the second year following the date as of which the Fund’s registration statement on Form N-2 is initially declared effective. Effective July 29, 2022, the Fund and PIMCO amended and restated the management fee waiver agreement such that PIMCO has contractually agreed to waive: (1) 70% of the management fees it is entitled to receive from the Fund for the period of July 29, 2022 through November 3, 2023; and (2) 35% of the management fees it is entitled to receive from the Fund for the period of November 4, 2023 through November 3, 2024.

Accordingly, any disclosure in the Prospectus or SAI related to PIMCO’s management fee waiver for the Fund is hereby supplemented with such information.

Investors Should Retain This Supplement for Future Reference

EMFLX_SUPP1_080422